简体
  • 简体中文
  • 繁体中文

热门资讯> 正文

Alphamab肿瘤学部门与生物制品制造商续签财产和设备租赁协议;股价下滑5%

2022-01-04 11:36

10:30 PM EST, 01/03/2022 (MT Newswires) -- Alphamab Oncology (HKG:9966) unit Jiangsu Alphamab Biopharmaceuticals renewed a property and equipment lease agreement with biologics manufacturer Suzhou Alphamab for another two years from Jan. 1, 2022 to March 31, 2024, according to a late Monday filing.

The new deal comes as the lease agreement secured in 2019 expired on Dec. 31, 2021.

Jiangsu Alphamab will pay Suzhou a rental fee of 838,900 yuan ($132,000) per month to lease the 2,235-square-meter premises of a building in China's Jiangsu province, used for biologics manufacturing and relevant materials storage.

The drugmaker said the lease amount will be settled on a quarterly basis.

Shares fell over 5% recently.

风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。